Purified anti-β-Amyloid, 1-16 Antibody (Previously Covance catalog# SIG-39320)

Pricing & Availability
6E10 (See other available formats)
Other Names
AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, Amyloid beta A4 protein, preA4, protease, peptidase nexin-II, beta-amyloid peptide, alzheimer disease amyloid protein, cerebral vascular amyloid peptide, APP, Amyloid Precursor Protein
Signet Catalog# 9320-02
Signet Catalog# 9320-05
Signet Catalog# 9320-10
Covance Catalog# SIG-39320
Mouse IgG1
Ave. Rating
5 reviews
Product Citations
Western blot of purified anti-β-amyloid, 1-16 antibody (clone 6E10). Lane 1: Molecular weight marker; Lane 2: 50 ng of the human Aβ1-40 peptide; Lane 3: 50 ng of the Aβ1-42 peptide; Lane 4: 50 ng of the recombinant human APP751 protein; Lane 5: 20µg of the human brain lysate; Lane 6: 50 ng of the rodent Aβ1-42 peptide. The blot was incubated with 1 µg/mL of the primary antibody overnight at 4°C, followed by incubation with the HRP goat anti-mouse IgG antibody (Cat. No. 405306). Enhanced chemiluminescence was used as the detection system.
  • A_6E10_PURE_betaAmyloid_1-16_WB_050818
    Western blot of purified anti-β-amyloid, 1-16 antibody (clone 6E10). Lane 1: Molecular weight marker; Lane 2: 50 ng of the human Aβ1-40 peptide; Lane 3: 50 ng of the Aβ1-42 peptide; Lane 4: 50 ng of the recombinant human APP751 protein; Lane 5: 20µg of the human brain lysate; Lane 6: 50 ng of the rodent Aβ1-42 peptide. The blot was incubated with 1 µg/mL of the primary antibody overnight at 4°C, followed by incubation with the HRP goat anti-mouse IgG antibody (Cat. No. 405306). Enhanced chemiluminescence was used as the detection system.
  • B_6E10_PURE_betaAmyloid_1-16_DirectELISA_050818
    Direct ELISA of purified anti-β-amyloid 1-16 (clone 6E10) antibody binding to the plate-immobilized human Aβ1-40 and the recombinant human APP751. ELISA was performed by coating the wells with 100 ng of peptide or recombinant protein. The wells were then incubated with the primary antibody at 37°C for 45 minutes, followed by incubation with HRP labeled goat anti-mouse IgG secondary antibody. TMB (3, 3', 5, 5' tetramethylbenzidine, Cat. No. 421501) was used as the detection system.
  • C_6E10_PURE_betaAmyloid_1-16_IHCP_050818
    IHC staining of purified anti-β-Amyloid, 1-16 antibody (clone 6E10) on the formalin-fixed paraffin-embedded normal human (left panel) and Alzheimer’s disease (right panel) brain tissues. Following antigen retrieval using 70% formic acid for 20 minutes, the tissues were incubated with 1µg/mL of the primary antibody for 1 hour at room temperature. BioLegend’s Ultra-Streptavidin (USA) HRP Detection Kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The images were captured with a 40X objective. Scale bar: 50 µm
Cat # Size Price Quantity Avail. Save
803004 25 µL 76€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
803001 200 µL 378€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
803002 500 µL 738€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
803003 1 mL 1.215€
Check Availability

Need larger quantities of this item?
Request Bulk Quote

Alzheimer's disease is characterized by the accumulation of aggregated Aβ peptides in senile plaques and vascular deposits. Aβ peptides are derived from amyloid precursor proteins (APP) through sequential proteolytic cleavage of APP by β-secretases and γ-secretases generating diverse Aβ species. Aβ can aggregate to form soluble oligomeric species and insoluble fibrillar or amorphous assemblies. Some forms of the aggregated peptides are toxic to neurons.

Product Details
Technical Data Sheet (pdf)

Product Details

Antibody Type
Host Species
Phosphate-buffered solution (no preservatives or carrier proteins).
The antibody was purified by affinity chromatography.
1 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check your vial or your CoA to find the most accurate storage condition for this antibody.

WB - Quality tested
Direct ELISA, IHC-P Validated
IHC-F, EM, ICC -  Reported in the literature

Recommended Usage

Each lot of this antibody is quality control tested by western blotting. For western blotting, the suggested use of this reagent is 1 µg/mL. For Direct ELISA, the suggested use of this reagent is 0.002 - 0.02 µg/mL. For immunohistochemistry on formalin-fixed paraffin-embedded tissue sections, the suggested use of this reagent is 0.2 - 5.0 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

This antibody is reactive to amino acid residue 1-16 of beta amyloid. The epitope lies within amino acids 3-8 of beta amyloid (EFRHDS).

This antibody clone has been reported for use in immunohistochemistry of free-floating sections2,13.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References
  1. Thakker DR, et al. 2009. Proc. Natl. Acad. Sci. USA. 106(11):4501-6. (IHC) PubMed
  2. Oddo S, et al. 2005. Proc. Natl. Acad. Sci. USA. 102(8):3046-51. (IHC-other) PubMed
  3. Herzig M, et al. 2004. Nat. Neuro. 7(9):954-959. (WB) PubMed
  4. Zheng Y, et al. 2012. PLoS One 6:39035. (IHC-F) PubMed
  5. Abramowksi D, et al. J Neurosci. 32:1273. (WB) PubMed
  6. Forny-Germano L, et al. 2014. J. Neurosci. 34:13629. (WB, IHC) PubMed
  7. Gowert NS, et al. 2014. PLoS One 2:e90523. (ICC, EM) PubMed
  8. Sandoval-Hernández A, et al. 2015. PLoS One. 10: 0145467. (IHC-F)
  9. Kumar R, et al. 2016. Brain. 139:174-92 (WB)
  10. Miyamoto T, et al. 2016. J. Biol. Chem. 291:1719-34. (WB)
  11. Saito S, et al. 2017. Acta Neuropathol. Commun. 5:26-9. (IHC-P) PubMed
  12. Omata Y, et al. 2016. Aging (Albany NY) 8(3):427. (IHC-P) PubMed
  13. Peng W, et al. 2016. Neurobiol. Dis. 93:215. (IHC-other) PubMed
  14. Mandler M, et al. 2015. PLoS One. e0115237. (WB, IHC, ELISA) PubMed
Product Citations
  1. Sandoval-Hernández A, et al. 2015. PLoS One. 10: 0145467. PubMed
  2. Kumar R, et al. 2016. Brain. 139: 174 - 192. PubMed
  3. Miyamoto T, et al. 2016. J Biol Chem. 291: 1719 - 1734. PubMed
  4. Baruch K, et al. 2016. Nat Med. 22:135-137. PubMed
  5. Fu A, et al. 2016. Proc Natl Acad Sci U S A. 113: 2705 - 2713. PubMed
  6. Donner L, et al. 2016. Sci Signal. 9: ra52. PubMed
  7. Cifelli J, et al. 2016. J Biol Chem. 291: 11981 - 11992. PubMed
  8. Hernandez-Rapp J, et al. 2016. Sci Rep. 6:30953. PubMed
  9. Pan H, et al. 2016. Stem Cell Reports. 7:707-718. PubMed
  10. Salta E, et al. 2016. EMBO Mol Med. 8: 1005 - 1018. PubMed
  11. Sherman M, et al. 2016. J Neurosci. 36: 9647 - 9658. PubMed
  12. Reinders N, et al. 2016. Proc Natl Acad Sci U S A. 113: E6526 - E6534. PubMed
  13. Hostetler E, et al. 2016. J Nucl Med. 57: 1599 - 1606. PubMed
  14. A Kimura, S Hata, T Suzuki 2016. J Biol Chem. 291: 24041 - 24053. PubMed
  15. Daria A, et al. 2017. EMBO J. 10.15252/embj.201694591. PubMed
  16. Flanagan M, et al. 2017. J Neuropathol Exp Neurol. 10.1093/jnen/nlw104. PubMed
  17. Yang S, et al. 2017. EMBO Mol Med. 9(1):61-77. PubMed
  18. Augé E, et al. 2017. Sci Rep. 7:41807. PubMed
  19. Willén K, et al. 2017. Mol Neurodegener. 10.1186/s13024-017-0203-y. PubMed
  20. Rocchi A, et al. 2017. PLoS Genet.. 10.1371/journal.pgen.1006962. PubMed
  21. Park J,et al. 2017. J Radiat Res.. 10.1093/jrr/rrx045. PubMed
  22. Zhi D, et al. 2017. Sci Rep. 10.1038/s41598-017-11628-9. PubMed
  23. Chen L, et al. 2017. Sci Rep. 10.1038/s41598-017-12484-3. PubMed
  24. Faraz A, et al. 2017. Antioxid Redox Signal. . 10.1089/ars.2016.6860. PubMed
  25. Casali BT, et al. 2018. J Neuroinflammation. 15:43. PubMed
  26. Matthes F, et al. 2018. Cell Death Discov. 4:4. PubMed
  27. Kim W, et al. 2018. Mol Neurodegener. 13:6. PubMed
  28. Pan RY, et al. 2019. Sci Adv. 5:eaau6328. PubMed
  29. Chiang ACA, et al. 2018. Am J Pathol. 188:739. PubMed
  30. Kulas JA, et al. 2017. J Endocrinol. 235:49. PubMed
  31. Yang C, et al. 2017. Autophagy. :0. PubMed
  32. Bartolotti N, et al. 2018. J Alzheimers Dis. 66:1425. PubMed
  33. Sun J, et al. 2019. Nat Commun. 10:53. PubMed
  34. Limbocker R, et al. 2019. Nat Commun. 10:225. PubMed
  35. Leonetti M, et al. 2019. Sci Rep. 9:4591. PubMed
  36. Harach T, et al. 2017. Sci Rep. 7:41802. PubMed
  37. Poksay KS, et al. 2017. Front Pharmacol. 8:46. PubMed
  38. Xia F, et al. 2017. Neuropsychopharmacology. 42:2493. PubMed
  39. Wang X, et al. 2017. Front Aging Neurosci. 9:157. PubMed
  40. Chandramowlishwaran P, et al. 2018. J Biol Chem. 293:3436. PubMed
  41. Song M, et al. 2018. Genes (Basel). 9:. PubMed
  42. Dong ZZ, et al. 2018. Int J Ophthalmol. 11:747. PubMed
  43. Rosenzweig N, et al. 2019. Nat Commun. 10:465. PubMed
  44. Sri S, et al. 2019. Acta Neuropathol Commun. 7:25. PubMed
  45. Feng T, et al. 2017. J Biol Chem. 292:1679. PubMed
  46. Garcia–Esparcia P, et al. 2017. Front Neurol. 8:89. PubMed
  47. Amar F, et al. 2017. Sci Signal. 10:478. PubMed
  48. López–Arias B, et al. 2017. PLoS One. 12:e0177541. PubMed
  49. Hu X, et al. 2017. Front Neuroanat. 11:45. PubMed
  50. Li N, et al. 2017. Curr Alzheimer Res. 14:1109. PubMed
  51. O'Reilly MA, et al. 2017. Theranostics. 7:3573. PubMed
  52. Welty S, et al. 2018. J Biol Chem. 293:1353. PubMed
  53. Ziegler–Waldkirch S, et al. 2018. EMBO J. 37:167. PubMed
  54. Ayaki T, et al. 2018. J Neuropathol Exp Neurol. 77:128. PubMed
  55. Lim CS, et al. 2018. Biosci Rep. 38:1. PubMed
  56. Söllvander S, et al. 2018. J Neuroinflammation. 15:98. PubMed
  57. Dyer M, et al. 2019. Front Aging Neurosci. 11:68. PubMed
  58. Grant MKO, et al. 2019. Biol Proced Online. 21:6. PubMed
  59. Lin TW, et al. 2017. PLoS One. 12:e0174561. PubMed
  60. Finke JM, et al. 2017. Biochim Biophys Acta. 1861:2228. PubMed
  61. Kedia N, et al. 2017. Phys Chem Chem Phys. 19:18036. PubMed
  62. Zhang JH, et al. 2018. BMC Complement Altern Med. 18:167. PubMed
  63. González C, et al. 2018. Mol Psychiatry. 23:2363. PubMed
  64. Fowler AJ, et al. 2019. Drugs R D. 19:149. PubMed
  65. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  66. Kiyota T, et al. 2018. J Neuroimmunol. 319:80. PubMed
  67. Chandra S, et al. 2019. J Alzheimers Dis Rep. 3:149. PubMed
  68. Datta M, et al. 2018. Immunity. 48:514. PubMed
  69. Gulisano W, et al. 2019. J Neurosci. 39:5986. PubMed
  70. Harper MM, et al. 2019. Invest Ophthalmol Vis Sci. 60:2716. PubMed
  71. Jonson M, et al. 2018. Cell Chem Biol. 25:595. PubMed
  72. Roitenberg N, et al. 2018. EMBO Rep. 19. PubMed
  73. Baek SH, et al. 2017. J Neurosci. 37:5099. PubMed
  74. Croft CL, et al. 2017. Cell Death Dis. 8:e2671. PubMed
  75. Valls–Comamala V, et al. 2017. Oncotarget. 8:41154. PubMed
  76. Paula PC, et al. 2019. Molecules. 24. PubMed
  77. Esposito G, et al. 2019. Mar Drugs. 17. PubMed
  78. Khan I, et al. 2018. Sci Rep. 8:12834. PubMed
  79. Bearer EL, et al. 2018. Neurobiol Aging. 70:276. PubMed
  80. Wendeln AC, et al. 2018. Nature. 556:332. PubMed
  81. Vargas–Restrepo F, et al. 2018. Biomedica. 38:69. PubMed
  82. Yadav DB, et al. 2017. Br J Pharmacol. 174:4173. PubMed
  83. Opazo P, et al. 2018. Cell Rep. 23:3137. PubMed
  84. Herzer S, et al. 2018. Front Mol Neurosci. 11:206. PubMed
  85. Plá V, et al. 2017. Front Mol Neurosci. 10:202. PubMed
  86. Spitzer P, et al. 2018. Front Aging Neurosci. 10:152. PubMed
  87. Serra–Batiste M, et al. 2018. Front Mol Biosci. 5:38. PubMed
  88. de Dios C, et al. 2019. Redox Biol. 26:101283. PubMed
  89. Kirouac L et al. 2015. eNeuro. 4(2) pii: ENEURO. PubMed
  90. Aisling Chaney et al. 2017. Journal of neurochemistry. 144(3):318-335 . PubMed
  91. Ahmad F et al. 2018. Scientific reports. 8(1):13119 . PubMed
  92. Hung COY et al. 2018. Cell reports. 25(13):3647-3660 . PubMed
  93. Xu L et al. 2019. Cell reports. 27(4):1293-1306 . PubMed
  94. Lisa Dolfe et al. 2018. Journal of Alzheimer's disease reports. 2(1):27-39 . PubMed
  95. Merlini M et al. 2019. Neuron. 101(6):1099-1108 . PubMed
  96. Fiock KL et al. 2019. J Comp Neurol. 528(1):108-113 . PubMed
  97. Cecon E et al. 2019. Br J Pharmacol. 176(18):3475-3488 . PubMed
  98. Cline EN et al. 2018. Journal of neurochemistry. 148(6):822-836 . PubMed
  99. Abud EM et al. 2017. Neuron. 94(2):278-293 . PubMed
  100. Sebollela A et al. 2017. Journal of neurochemistry. 142(6):934-947 . PubMed
  101. Ye X et al. 2017. The Journal of Neuroscience. 37(10):2639-2655 . PubMed
  102. Huynh TV et al. 2017. Neuron. 96(5):1013-1023 . PubMed
  103. Nobili A et al. 2017. Nature communications. 253:27:00 . PubMed
Publication Library
AB_2715854 (BioLegend Cat. No. 803004)
AB_2564653 (BioLegend Cat. No. 803001)
AB_2564654 (BioLegend Cat. No. 803002)
AB_2564652 (BioLegend Cat. No. 803003)

Antigen Details

Amyloid precursor protein is a 770 amino acid protein with a molecular mass of ~100 kD. According to the UniProtKB database, APP (ID# P05067) has 11 isoforms (34 to ~90 kD) and the 770 form has been designated as the canonical form. Isoform APP695 is the predominant form expressed in neuronal tissue. Isoforms APP751 and APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Aβ denotes peptides of 36-43 amino acids generated from cleavage of APP by secretases. Aβ has an apparent molecular mass of about 4 kD.

Tissue distribution: Primarily nervous system, but also adipose tissue, intestine, muscle.
Cellular distribution: Cytosol, endosomes, nucleus, plasma membrane, extracellular, and golgi apparatus.

The normal function of Aβ is not well understood. Several potential physiological roles have been proposed, including: activation of kinase enzymes; protection against oxidative stress; regulation of cholesterol transport; transcription factor, and as an anti-microbial agent.
Biology Area
Cell Biology, Neurodegeneration, Neuroscience, Protein Misfolding and Aggregation
Molecular Family
Antigen References
  1. Kumar A, et al. 2015. Pharmacol. Rep. 67(2):195.
  2. Sadigh-Eteghad S, et al. 2015. Med. Princ. Pract. 24(1):1
  3. Hampel H, et al. 2015. Expert Rev. Neurother. 15(1):83.
  4. Puig KL, et al. 2012.  Exp. Gerontol. 48(7): 608.
  5. Selkoe DJ, et al. 2016. EMBO Mol. Med. 8(6):595.
  6. Walsh DM, et al.  2007. J. Neurochem. 101(5):1172.
Gene ID
351 View all products for this Gene ID
View information about beta-Amyloid, 1-16 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 4    Revision Date: 05-08-2018

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login / Register
Forgot your password? Reset password?
Create an Account